Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals PIC

Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103

Fineline Cube Aug 31, 2026
Company Deals PIC

Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline

Fineline Cube Aug 31, 2026
Company Drug PIC

Eli Lilly Wins FDA Approval for Mounjaro Cardiovascular Risk Reduction in Type 2 Diabetes

Fineline Cube Aug 31, 2026
Company Drug PIC

Takeda Wins FDA Approval for MIMRYLO, First‑in‑Class Hepcidin Mimetic for Polycythemia Vera

Fineline Cube Aug 31, 2026
Company Deals PIC

AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline

Fineline Cube Aug 28, 2026
Company Deals PIC

Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103

Fineline Cube Aug 31, 2026
Policy / Regulatory

GluBio’s GLB‑005 WIZ Degrader Enters NMPA Rare Disease Pilot for β‑Thalassemia

Fineline Cube Aug 31, 2026
Company Deals PIC

Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103

Fineline Cube Aug 31, 2026
Company Drug

Shanghai HeartCare Medical Secures Taiwan Approval for Homegrown Femoral Artery Occluder

Fineline Cube Jul 16, 2024

Shanghai HeartCare Medical Technology Co., Ltd (HKG: 6609), a leading player in the Chinese medical...

Drug Legal / IP Policy / Regulatory

U.S. Senate Passes Affordable Prescriptions for Patients Act to Limit Patent Thicketing

Fineline Cube Jul 15, 2024

In a significant move to curb drug prices, the U.S. Senate unanimously passed the Affordable...

Company Deals

Nona Biosciences Partners with Alaya.bio to Revolutionize CAR-T Therapy Development

Fineline Cube Jul 15, 2024

Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a strategic...

Company Drug

Eisai’s Next-Gen SERD, Orserdu, Begins Real-World Study in Shanghai Ruijin Hospital’s Hainan Subsidiary

Fineline Cube Jul 15, 2024

Shanghai Ruijin Hospital’s Hainan subsidiary has initiated a real-world study for Orserdu (elacestrant), a next-generation...

Company Drug

Everest Medicines’ Velsipity Shows Positive Results in Largest Asian Phase III UC Trial

Fineline Cube Jul 15, 2024

Everest Medicines (HKG: 1952), a leading biopharmaceutical company based in China, has announced positive top-line...

Company Drug

Huadong Medicine’s Partner Arcutis Gets FDA Nod for Roflumilast Cream

Fineline Cube Jul 15, 2024

Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, announced that its co-development partner...

Company Deals Medical Device

Mindray Bio-Medical Partners with Nanjing Municipal Government to Boost Healthcare Innovation

Fineline Cube Jul 15, 2024

Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760), a leading player in the global medical...

Company Deals

Shenzhen-Based National Biological Manufacturing Innovation Center Breaks Ground

Fineline Cube Jul 15, 2024

Construction has commenced on a pioneering national biological manufacturing industry innovation center in Shenzhen, marking...

Company Deals Digital

E-Health Now Secures USD 13.8 Million in Series C Financing to Expand AI Medical Services

Fineline Cube Jul 15, 2024

E-Health Now, a China-based one-stop artificial intelligence (AI)-powered medical health service platform, has reportedly secured...

Company

Merck KGaA Launches First GMP Cell Culture Medium Production Line in China

Fineline Cube Jul 15, 2024

German pharmaceutical giant Merck KGaA (ETR: MRK) has announced the commencement of commercial manufacturing of...

Company Deals

AusperBio Secures $37 Million in Series A Funding to Advance Hepatitis B Therapy AHB-137

Fineline Cube Jul 15, 2024

AusperBio, a sino-American biotechnology company specializing in liver therapy development, has reportedly secured USD 37...

Company Drug

Mabwell Bioscience’s 9MW2821 Earns FDA Fast Track Designation for Triple Negative Breast Cancer

Fineline Cube Jul 15, 2024

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced...

Company Deals

Shanghai Duoning Biotechnology Partners with BASF SE to Commercialize Medical Materials in China

Fineline Cube Jul 15, 2024

Shanghai Duoning Biotechnology Co., Ltd, a prominent player in China’s biopharmaceutical industry, has entered into...

Company Drug

NMPA Accepts 3SBio’s Filing for Anemia Treatment SSS06, Potential Game Changer for Dialysis Patients

Fineline Cube Jul 15, 2024

3SBio Inc. (HKG: 1530), a leading biopharmaceutical company based in China, has announced that the...

Company Deals

Baheal Pharmaceutical Group to Launch Industry Fund Focused on Life Sciences

Fineline Cube Jul 15, 2024

China’s leading health services and distribution conglomerate, Baheal Pharmaceutical Group, is venturing into the investment...

Company Deals Drug

Huadong Medicine Secures Exclusive Rights to Oral Edaravone Candidate TTYP01 in Major Licensing Deal

Fineline Cube Jul 15, 2024

Huadong Medicine Co., Ltd (SHE: 000963), a prominent pharmaceutical company in China, has entered into...

Company Drug

Oricell Therapeutics’ GPRC5D-Targeted CAR-T Therapy Earns FDA Fast Track for Multiple Myeloma

Fineline Cube Jul 15, 2024

Oricell Therapeutics Co., Ltd, a leading biopharmaceutical company based in China, has announced that it...

Company Deals

Legend Biotech’s Shares Leap on Acquisition Rumors; Parent Genscript Biotech Corp. Follows Suit

Fineline Cube Jul 15, 2024

Chinese biopharmaceutical firm Legend Biotech (NASDAQ: LEGN), a specialist in chimeric antigen receptor (CAR) T-cell...

Company R&D

Oxford Study Clears Semaglutide of Neuro/Psychiatric Risks, Suggests Cognitive and Addiction Benefits

Fineline Cube Jul 15, 2024

Researchers at the prestigious Oxford University in the UK have unveiled groundbreaking real-world data on...

Company Drug

Simcere Pharmaceutical’s COVID-19 Therapy Xiannuoxin Earns Full Approval in China

Fineline Cube Jul 12, 2024

Simcere Pharmaceutical Group (HKG: 2096), a biopharmaceutical company based in China, has announced that its...

Posts pagination

1 … 378 379 380 … 713

Recent updates

  • GluBio’s GLB‑005 WIZ Degrader Enters NMPA Rare Disease Pilot for β‑Thalassemia
  • Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103
  • Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline
  • Eli Lilly Wins FDA Approval for Mounjaro Cardiovascular Risk Reduction in Type 2 Diabetes
  • Takeda Wins FDA Approval for MIMRYLO, First‑in‑Class Hepcidin Mimetic for Polycythemia Vera
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

GluBio’s GLB‑005 WIZ Degrader Enters NMPA Rare Disease Pilot for β‑Thalassemia

Company Deals PIC

Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103

Company Deals PIC

Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline

Company Drug PIC

Eli Lilly Wins FDA Approval for Mounjaro Cardiovascular Risk Reduction in Type 2 Diabetes

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.